United Therapeutics (UTHR) - רווח נקי למניה (EPS TTM)

United Therapeutics is implementing energy-efficient systems and solar power generation across its centers. The company is developing carbon-neutral, LEED-certified laboratories for the creation of transplants. This rolling annual earnings per share chart visualizes the income trend, where the value 26.68 serves as the baseline indicator. Leadership in pulmonary hypertension therapy and a monopoly in the orphan segment provide the business with significant pricing power and a stable cash flow.
פילוחי מדדים מקיפים ואנליטיקה עבור United Therapeutics Corp. (UTHR)

This indicator is calculated as the ratio of the company's total net income to the total number of shares outstanding over a rolling year, measuring the actual efficiency of shareholder value generation. By analyzing the 12-month net income per share snapshot, an investor can promptly detect the erosion of United Therapeutics (UTHR) margins resulting from the expansion of pharma behemoths into the narrow pulmonary hypertension therapy niche.